aTyr Pharma, Inc.
NASDAQ:ATYRBiotechnology
Healthcare
$0.53 +14.23%
+$0.07 today
- Market cap
- $52.13M
- Beta
- 0.54
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$0.71
52W Low $0.40High $7.29
Volume 1.02M
Average 2.29M
Income Statement
Follow revenue through to earnings.
Revenue
$190,000.00
FY 2025 · Annual
-19.1% YoYOperating Income
-$77.63M
FY 2025 · Annual
Net Income
-$74.12M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 10.39M | 353K | 235K | 190K |
| Cost of Revenue | 1.3M | 1.7M | 0 | 0 | 1.55M |
| Gross Profit | (1.3M) | 8.69M | 353K | 235K | (1.36M) |
| Gross Margin | — | 83.7% | 100.0% | 100.0% | -717.4% |
| Research & Development | 23.26M | 42.81M | 42.29M | 54.37M | 60.22M |
| Selling, General & Admin | 10.75M | 12.29M | 12.98M | 13.78M | 17.6M |
| Operating Expenses | 32.71M | 55.1M | 55.27M | 68.15M | 76.26M |
| Depreciation & Amortization | 1.3M | 1.7M | 2.74M | 1.54M | 1.55M |
| EBITDA | (32.47M) | (43.65M) | (47.66M) | (62.48M) | (72.57M) |
| EBITDA Margin | — | -420.3% | -13500.3% | -26588.1% | -38192.1% |
| Operating Income | (34.02M) | (46.4M) | (54.92M) | (67.91M) | (77.63M) |
| Operating Margin | — | -446.8% | -15557.8% | -28899.6% | -40856.3% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 238K | 1.06M | 4.52M | 3.89M | 3.51M |
| Income Before Tax | (33.78M) | (45.34M) | (50.4M) | (64.02M) | (74.12M) |
| Pre-Tax Margin | — | -436.6% | -14276.8% | -27243.4% | -39009.5% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (33.77M) | (45.34M) | (50.39M) | (64.02M) | (74.12M) |
| Net Margin | — | -436.5% | -14274.5% | -27243.8% | -39009.5% |
| EPS (Basic) | (1.77) | (1.60) | (0.94) | (0.86) | (0.80) |
| EPS (Diluted) | (1.77) | (1.60) | (0.94) | (0.86) | (0.80) |
| 19.08M | 28.42M | 53.61M | 74.26M | 92.99M | |
| 19.08M | 28.42M | 53.61M | 74.26M | 92.99M |
ATYR Earnings Waterfall · TTM
NASDAQ:ATYR · Revenue to Net Income
Key Ratios
EPS$-0.73
Gross Margin-2886.8%
Net Margin-3387.4%
P/E Ratio-2.4
P/S Ratio92.2
Analysis
$190.0K of revenue converted into -$70.0M of net income for the selected period. Gross margin is -2886.8% and net margin is -3387.4%, showing how much revenue survives after costs and taxes. EPS is $-0.73, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| S-8 | S-8 filing | Aug 7, 2026 | |
| 8-K | Current report | Aug 7, 2026 | |
| 10-Q | Quarterly report | Aug 7, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 6, 2026 | |
| 8-K | Current report | Jul 31, 2026 |
How much revenue does ATYR generate?
aTyr Pharma, Inc. (ATYR) reported $190,000.00 of revenue in fiscal 2025.
Is ATYR profitable?
aTyr Pharma, Inc. (ATYR) reported -$74.12M of net income, with a net margin of -39009.5%.
Continue the stock analysis
Jump to another research area for this company.